Multiplex Biomarker Imaging Market Report 2026

The multiplex biomarker imaging market size has grown rapidly in recent years. It will grow from $0.54 billion in 2025 to $0.6 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rise in cancer research studies, increased need for biomarker-based analysis, early adoption of fluorescence imaging, limited single-marker analysis capabilities, growth of molecular pathology testing.

The multiplex biomarker imaging market size is expected to see strong growth in the next few years. It will grow to $0.86 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in imaging platforms, rising demand for personalized medicine, expansion of multiplex assay applications, growth in pharmaceutical biomarker programs, increased investment in spatial biology research. Major trends in the forecast period include increasing use of multiplex imaging in oncology research, growing demand for high-resolution tissue mapping, rising adoption of advanced immunofluorescence techniques, expansion of automated image analysis solutions, integration of multiplex imaging with drug discovery platforms.

The rising prevalence of chronic diseases is expected to drive the growth of the multiplex biomarker imaging market. Chronic diseases are long-term health conditions that persist or recur over time, often influenced by multiple risk factors, complex causes, and extended latency periods. Factors such as population aging, improved disease detection, enhanced treatment, and lifestyle and environmental changes contribute to the growing prevalence of chronic conditions. Multiplex biomarker imaging plays a key role in chronic disease management by enabling comprehensive analysis of disease progression and treatment responses. For instance, in January 2023, according to the National Institutes of Health (NIH), a US-based biomedical research agency, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.52 million in 2020 to 142.66 million in 2050. Therefore, the rising prevalence of chronic diseases is driving the multiplex biomarker imaging market.

Major companies in the multiplex biomarker imaging market are introducing innovations such as automated slide loaders to improve imaging efficiency and throughput. Automated slide loaders streamline sample handling, reduce hands-on time, and enable high-volume multiplex biomarker imaging experiments. For example, in April 2024, Standard BioTools Inc., a US-based provider of analytical systems, launched the Hyperion XTi Imaging System with a high-throughput multiplexed whole slide feature. The system offers three modes - preview, tissue, and cell - allowing researchers to quickly visualize tissue heterogeneity and perform in-depth analyses. Utilizing imaging mass cytometry (IMC), this method achieves up to 10 times higher throughput than cyclic immunofluorescent imaging, while the automated slide loader enhances standardization and efficiency, accelerating advances in spatial proteomics for reliable insights into health and disease.

In March 2024, Calyx, a UK-based medical imaging services provider, merged with Invicro, a US-based quantitative imaging biomarker company, to form a global leader in medical imaging and software solutions. This merger combines expertise and specialized support to offer a differentiated proposition for biopharma clients, from large pharmaceutical companies to specialty biotech firms, strengthening the multiplex biomarker imaging market with expanded capabilities and comprehensive solutions.

Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies.

North America was the largest region in the multiplex biomarker imaging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiplex biomarker imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imaging instruments, imported reagents, and laboratory software have increased procurement and manufacturing costs in the multiplex biomarker imaging market, particularly affecting clinical labs and research institutes dependent on foreign hardware. These tariffs contribute to higher pricing and slower adoption in regions reliant on imported imaging systems. However, they also encourage domestic production of imaging instruments and software, driving innovation, regional manufacturing growth, and improved supply chain resilience over time.

The multiplex biomarker imaging market research report is one of a series of new reports that provides multiplex biomarker imaging market statistics, including multiplex biomarker imaging industry global market size, regional shares, competitors with a multiplex biomarker imaging market share, detailed multiplex biomarker imaging market segments, market trends and opportunities, and any further data you may need to thrive in the multiplex biomarker imaging industry. This multiplex biomarker imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multiplex biomarker imaging is a technique that enables the simultaneous detection and analysis of multiple biomarkers within a single sample, allowing visualization of complex biological processes and molecular profiles. This method employs advanced imaging technologies to map the spatial distribution of biomarkers in tissues, providing detailed insights into cellular interactions and microenvironments.

The main components of multiplex biomarker imaging include instruments, software, and services. Instruments are tools or devices used to perform specific tasks, particularly scientific measurements such as speed, height, or sound. Imaging techniques include immunofluorescence (IF) assays, tissue microarray (TMA) assays, immunohistochemistry (IHC) assays, fluorescence in situ hybridization (FISH) assays, and toponome imaging systems (TIS), applied in areas such as drug safety, oncology studies, and genetic characterization. End users include research institutes (government and private), clinical laboratories, pharmaceutical companies, and biotechnology organizations.

The multiplex biomarker imaging market consists of revenues earned by entities by providing services such as imaging and analysis services, pathology services, and clinical and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiplex biomarker imaging market also includes sales of imaging instruments, reagents and kits, software, and analysis tools that are used in providing multiplex biomarker imaging services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.